International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

Last updated: May 2, 2022
Sponsor: Azienda Ospedaliero-Universitaria Careggi
Overall Status: Active - Recruiting

Phase

N/A

Condition

Kidney Cancer

Renal Cell Carcinoma

Urologic Cancer

Treatment

N/A

Clinical Study ID

NCT05363657
i-RECORd
  • Ages > 18
  • All Genders

Study Summary

Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications, approaches, techniques for PN, and correct reporting of outcomes, are still a matter of great debate within the urology community. Concurrently, case-report series suggested that alternative strategies for the treatment of localized renal tumors (ablation techniques (AT), watchful waiting (WW), active surveillance (AS)) could be feasible with acceptable oncologic outcomes in particular settings of patients with localized renal tumors. In this complex clinical scenario, the role surgeon-related and environmental factors (such as surgical experience, hospital resources, countries' social background and performance of health system) are important to address the best personalized approach in patients with renal tumors.

In the light of current evidence, many unsolved questions still remain and many unmet needs must be addressed. In particular, 1) the risk-benefit trade-offs between PN and RN for anatomically complex renal localized tumors; 2) the definition of evidence-based strategies to tailor the management strategy (AT vs WW vs AS vs surgery) in different subset of patients with particular clinical conditions (i.e. old, frail, comorbid patients); and 3) the definition of evidence-based recommendations to adapt surgical approach (open vs laparoscopic vs robotic) and resection techniques to different patient-, tumor-, and surgeon-specific characteristics.

To meet the challenges, to overcome the limitations of current kidney cancer literature (such as the retrospective study design, potential risk of biases, and heterogeneous follow-up of most series), and to provide high-quality evidence for future development of effective clinical practice Guidelines, we designed the international REgistry of COnservative or Radical treatment of localized kiDney tumors (i-RECORD) Project.

The expected impact of the i-RECORD project is to provide robust evidence on the leading clinical and environmental factors driving selection of the management strategy in patients with kidney cancer, and the differential impact of different management strategies (including AS, WW, AT, PN and RN) on functional, perioperative and oncological outcomes, as well as quality of life assessment, at a mid-long term follow-up (5-10 years).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Radiological diagnosis of renal tumor susceptible to active treatment or AS/WW.
  • Age ≥18 years
  • Informed consent signed

Exclusion

Exclusion Criteria:

  • Patient refuse to participate in clinical research.
  • Urothelial renal carcinoma.

Study Design

Total Participants: 10000
Study Start date:
January 10, 2022
Estimated Completion Date:
December 31, 2028

Study Description

Study design

The overall objective of the i-RECORD project is to build a multicentre multi-arm multi-stage prospective observational registry collecting data on the management of kidney cancer in consecutive patients treated at 50 tertiary referral Centers worldwide over a 2 years-period and with 5 years of follow-up

. On this registry, six prospective trials with specific objectives have been built.

The i-RECORd project is designed as an observational prospective longitudinal trial involving 50 international, very-high-volume tertiary referral Centers with extensive experience in management of kidney cancer. Centers will be included in the project only if they will be able to certify at least to: 1) perform 150 partial and radical nephrectomy/year, or 2) to perform 80 ATs/year, or 3) to include 50 patients in WW/AS protocols/year.

The enrollment and follow-up periods will be 2 and 5 years, respectively. The estimate of patients' enrollment over the study period is 10'000 inclusions.

The 50 Centers finally enrolled in the i-RECORD project will be given the access to a web-based platform for data collection for 24 months from the starting date of the project.

A web-based e-form platform will be used for data collection.

Data collection

This observational study aims to obtain controlled, qualitative and quantitative, data of the enrolled patients through a web-based e-form platform. For all patients it will be asked to complete a data collection form specifically designed for this study, consisting of some subfolders:

  1. Anthropometric, pre-operative and comorbidity data (patient characteristics).

  2. Imaging data e and pre-operative tumor features (tumor characteristics).

  3. Intra-operative and post-operative data (treatment characteristics).

  4. Histopathological analysis (tumor histopathological characteristics).

  5. Patients follow-up variables (at 6, 12, 24 and 60 months from the treatment) (follow-up characteristics).

Decision Analysis Modeling

Beyond traditional descriptive and inferential statistical analyses, the i-RECORd project will provide a comprehensive overview of the current selection criteria for each type of management option by applying innovative statistical methods (Decision Analysis Modeling through discrete choice models) to determine the differential impact of all potential relevant variables on the choice of treatment. To do so, we will consider specific clinical scenarios (clinical clusters) made of the integration of patient characteristics (comorbidity score, performance status, age, gender, etc.), patient-reported outcomes measures (PROMs), tumors anatomical features (degree of complexity, clinical diameter, side, location within the kidney, involvement of renal sinus or collecting system, etc.), surgeon-related factors (surgical experience and background), hospital economic availabilities (i.e. open, laparoscopic, robotic surgery) and other country-specific socio-economical features in order to determine the impact of such variables on the final choice of treatment.

By applying the discrete choice model to the analysis of the prospective dataset, the i-RECORd project will overcome the current state of the art in the treatment of localized renal tumors as it will show how the choice of treatment is performed by the decision-maker (at a surgeon- and hospital-level) in each specific clinical cluster of patients, why that choice was performed according to a careful analysis of the personalized patient setting and whether that choice will influence the postoperative outcomes.

Adapted MAMS Registry

The i-RECORD will be designed adapting the innovative concept of multi-arm, multi-stage (MAMS) platform randomized trials (used, for instance, for the design of the Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) Trial) to create a dynamic, observational registry evaluating simultaneously different management options in different patient- and/or tumor-related scenarios.

Connect with a study center

  • Medical University of Vienna, Vienna General Hospital

    Vienna, 1090
    Austria

    Active - Recruiting

  • University of Bruxelles

    Bruxelles, 1050
    Belgium

    Active - Recruiting

  • Onze Lieve Vrouw Hospital

    Leuven, 8500
    Belgium

    Active - Recruiting

  • University Hospitals Leuven

    Leuven, 3000
    Belgium

    Site Not Available

  • Santa Casa da Misericórdia de Fortaleza

    Fortaleza, 60025
    Brazil

    Active - Recruiting

  • University of Patras

    Patras, 265 04
    Greece

    Active - Recruiting

  • Urology, Andrology & Kidney Transplantation Unit, University of Bari

    Bari, 70121
    Italy

    Active - Recruiting

  • Policlinico S. Orsola Malpighi

    Bologna, 40138
    Italy

    Active - Recruiting

  • Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital

    Firenze, 50100
    Italy

    Active - Recruiting

  • Policlinico Riuniti, Università di Foggia.

    Foggia, 71122
    Italy

    Active - Recruiting

  • Division of Urology, University of Genoa,Policlinico San Martino Hospital

    Genova, 16132
    Italy

    Active - Recruiting

  • Azienda Ospedaliera Policlinico "G. Martino", Università di Messina.

    Messina, 98124
    Italy

    Active - Recruiting

  • Policlinico Istituto Europeo di Oncologia (IEO)

    Milano, 20141
    Italy

    Active - Recruiting

  • San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital

    Milano, 20132
    Italy

    Active - Recruiting

  • Istituto Nazionale dei Tumori Fondazione Senatore "G. Pascale"

    Napoli, 80131
    Italy

    Active - Recruiting

  • Institute Oncology Veneto (IOV)

    Padova, 35128
    Italy

    Active - Recruiting

  • Humanitas Hospital

    Rozzano, 20089
    Italy

    Active - Recruiting

  • Università degli Studi di Torino, Ospedale S. Luigi Gonzaga.

    Torino, 10043
    Italy

    Active - Recruiting

  • Università degli studi di Torino, Ospedale Molinette

    Torino, 10126
    Italy

    Active - Recruiting

  • AOUI Verona

    Verona, 37126
    Italy

    Active - Recruiting

  • Jikei University School of Medicine

    Tokyo, 105-8461
    Japan

    Site Not Available

  • Amsterdam University Medical Centers

    Amsterdam, 1118
    Netherlands

    Active - Recruiting

  • European Health Center

    Otwock, 05-400
    Poland

    Active - Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie

    Warsaw, 00-001
    Poland

    Active - Recruiting

  • N.N. Blokhin National Medical Research Center of Oncology

    Moscow, 119571
    Russian Federation

    Active - Recruiting

  • NG Teng Fong General Hospital

    Singapore, 6090606
    Singapore

    Active - Recruiting

  • Fundaciò Puigvert

    Barcelona, 08025
    Spain

    Active - Recruiting

  • Hospital Universitario Ramón y Cajal, University of Alcalá

    Madrid, 28034
    Spain

    Active - Recruiting

  • Bristol Urological Institute

    Bristol, BS10 5NB
    United Kingdom

    Active - Recruiting

  • Guy's Hospital

    London, SE1 9RT
    United Kingdom

    Active - Recruiting

  • Institute of Urology, University of Southern California.

    Los Angeles, California 90007
    United States

    Active - Recruiting

  • University of California San Diego, Moores Cancer Center

    San Diego, California 92037
    United States

    Active - Recruiting

  • Stanford University

    Stanford, California 94304
    United States

    Site Not Available

  • Loyola University Medical Center, Edward Hines VA Hospital

    Chicago, Illinois 60141
    United States

    Site Not Available

  • University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • VCU Health System

    Richmond, Virginia 23298
    United States

    Active - Recruiting

  • Swedish Hospital

    Seattle, Washington 98122
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.